Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050942 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
A Phase 3 study of Gastro-enteropancreatic Neuroendocrine Tumor, sponsored by Camurus AB.
- Active
- Registry status
- Phase 3
- Development phase
- 332
- Enrollment target
- 20
- Study locations
NCT05050942 is a Phase 3 study of Gastro-enteropancreatic Neuroendocrine Tumor that is active but no longer recruiting, run by Camurus AB. The registered enrollment target is 332 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05050942, a Phase 3 study of Gastro-enteropancreatic Neuroendocrine Tumor, is active but no longer recruiting, sponsored by Camurus AB.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 332 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Conditions Studied
Interventions
- DRUG Octreotide LAR
- DRUG CAM2029
- DRUG Lanreotide ATG
Study Locations (20)
Texas
- Texas Oncology - Austin - Austin
- Texas Oncology - Dallas - Dallas
- Texas Oncology - Denton North - Denton
- The University of Texas - MD Anderson Cancer Center - Houston
- Texas Oncology - McAllen - McAllen
- Texas Oncology - San Antonio Northeast - San Antonio
New York
- Memorial Sloan-Kettering Cancer Center - New York
- The Mount Sinai Hospital - The Bronx
- White Plains Hospital - Center for Cancer Care - White Plains
Florida
- Mayo Clinic Hospital - Florida - Jacksonville
- Anderson Family Cancer Institute - Jupiter
Arizona
- Mayo Clinic Cancer Center (MCCC) - Phoenix - Phoenix
California
- UCLA Ahmanson Biological Imaging Center - Santa Monica
Colorado
- Rocky Mountain Cancer Centers - Denver - Midtown - Denver
Kentucky
- University of Kentucky (UK) - Markey Cancer Center - Lexington
Louisiana
- East Jefferson General Hospital - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05050942
The ClinicalTrials.gov registry entry for NCT05050942 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Camurus AB, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastro-enteropancreatic Neuroendocrine Tumor appearing as the primary indexed condition, and to 3 interventions - of which Octreotide LAR is the first listed.
NCT05050942 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT05050942 about?
NCT05050942 is a clinical study titled "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET". The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with...
What is the current status of trial NCT05050942?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2021-10-22. Estimated completion is 2028-07.
What conditions does trial NCT05050942 study?
This clinical trial studies the following conditions: Gastro-enteropancreatic Neuroendocrine Tumor.
What interventions are being tested in trial NCT05050942?
The interventions under investigation include: Octreotide LAR (DRUG), CAM2029 (DRUG), Lanreotide ATG (DRUG).
Who is sponsoring clinical trial NCT05050942?
This trial is sponsored by Camurus AB, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05050942 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastro-enteropancreatic Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.